Nymox Pharmaceutical News (NASDAQ:NYMX)

DateTimeSource
Headline
05/31/201710:00AMGLOBESexual Function Improves in First-Line Patients Given Fexapotide Treatment in Nymox U.S. BPH Long-Term Clinical Trials
HASBROUCK HEIGHTS, N.J., May 31, 2017 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ:NYMX) is pleased to announce statistically significant clinical trial results showing that the Company's prostate enlargement (BPH) and prostate cancer drug Fexapotide Triflutate produced clinically important improvements... More...>>
05/10/201711:15AMGLOBENYMOX Files For Approval of First In Class Prostate Drug in Europe: Teleconference at 4:30 EDT
HASBROUCK HEIGHTS, N.J., May 10, 2017 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ:NYMX) will hold a teleconference call for shareholders today May 10 at 4:30 EDT. The call in number is 1-888-424-8151 and the passcode is 7826703# (for Canada please use 1-888-465-5079). Forward Looking Statements To the... More...>>
05/08/201711:00AMGLOBENYMOX Files For Approval of First In Class Prostate Drug in Europe: Company To Hold Teleconference Wednesday May 10 at 4:30 E...
HASBROUCK HEIGHTS, N.J., May 08, 2017 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ:NYMX) Following Nymox's announcement of the Company's filing for marketing approval of Fexapotide Triflutate for enlarged prostate (BPH) in Europe, Nymox is pleased to announce a teleconference with shareholders at 4:30 p.m... More...>>
05/03/20179:30AMGLOBENYMOX Files For Marketing Approval For Fexapotide Triflutate in Europe
HASBROUCK HEIGHTS, N.J., May 03, 2017 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ:NYMX) is pleased to announce today that the Company has filed to seek approval for marketing authorization for Fexapotide Triflutate in five European countries, comprising the Netherlands, the UK, Germany, France and Spain... More...>>
03/29/201710:45AMGLOBENymox Provides Update on Fexapotide Development
HASBROUCK HEIGHTS, N.J., March 29, 2017 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ:NYMX) provided an update today on the Company's development activities for Fexapotide Triflutate, its new drug for prostate enlargement. The Company is very pleased with the progress it has made, which is in line... More...>>
11/29/20169:45AMGLOBENymox Reports Additional Positive Results From Completed Fexapotide BPH Phase 3 Studies Showing Significant Early Response an...
HASBROUCK HEIGHTS, N.J., Nov. 29, 2016 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ:NYMX) is pleased to announce that new Phase 3 prospective randomized clinical trial results have confirmed that patients who received fexapotide as their initial treatment for BPH (prostate enlargement) had superior efficacy... More...>>
10/11/201610:00AMGLOBENymox Reports Successful New Phase 3 Long-Term Fexapotide Repeat Injection BPH Trial Results: Lasting Symptomatic Improvement...
HASBROUCK HEIGHTS, N.J., Oct. 11, 2016 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ:NYMX) is pleased to announce successful new study results from the long-term repeated injection group from the U.S. Phase 3 trials for fexapotide, the Company's lead compound in late stage development... More...>>
08/29/201610:30AMGLOBENymox's New Phase 3 Long-Term U.S. Results For Prostate Enlargement Drug Fexapotide Show 
1. Dramatic Decrease in Prostate Cancer and 2. Major Reduction in Need For BPH Prostate Surgery HASBROUCK HEIGHTS, N.J., Aug. 29, 2016 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (Nasdaq:NYMX) lead drug fexapotide which has been in development for over a decade and which has been tested by expert clinical trial... More...>>
08/24/201612:19PMGLOBENymox Reports Successful New Long-Term Fexapotide Placebo Crossover Study Results: Major Reduction in Incidence of Surgery
HASBROUCK HEIGHTS, N.J., Aug. 24, 2016 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ:NYMX) is pleased to announce successful new study results from the long-term blinded placebo crossover group from the U.S. Phase 3 trials for fexapotide, the Company's lead compound in late stage... More...>>
08/17/201610:00AMGLOBENymox Announces Private Placements of $2.24 Million
HASBROUCK HEIGHTS, N.J., Aug. 17, 2016 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ:NYMX) is pleased to announce that it has recently closed private placements and other investments in the Company for a total of $2.24 million. The investments totaled 965,649 shares at an average price of $2.32 with no warrants... More...>>
08/11/201610:28AMGLOBENymox Announces Prostate Drug Progress
HASBROUCK HEIGHTS, N.J., Aug. 11, 2016 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ:NYMX) is pleased to announce major progress in the evidence for the safety and efficacy of fexapotide, the Company's Phase 3 drug in the final stages of development for prostate enlargement (BPH) and for low grade prostate... More...>>
08/11/20165:00AMPRNUSNymox Pharmaceutical Corporation Investigated For Securities Fraud By Block & Leviton After Report Reveals Pervasive Miscondu...
Nymox Pharmaceutical Corporation Investigated For Securities Fraud By Block & Leviton After Report Reveals Pervasive Misconduct By The Company PR Newswire BOSTON, Aug. 11, 2016 BOSTON, Aug. 11, 2016 /PRNewswire/ -- Block & Leviton LLP (www.blockesq.com), a securities litigation firm representing investors nationwide... More...>>
08/10/201610:25PMBWIMPORTANT INVESTOR NOTICE: Lundin Law PC Announces an Investigation of Nymox Pharmaceutical Corp. & Advises Investors with Lo...
Lundin Law PC (http://lundinlawpc.com/) announces that it is investigating claims against Nymox Pharmaceutical Corporation (“Nymox” or the “Company”) (Nasdaq: NYMX) concerning possible violations of federal securities laws. To get more information about this investigation, please contact Brian Lundin, Esquire... More...>>
08/10/20164:53PMPRNUSSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nymox Pharmaceutical Corporation - NYMX
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nymox Pharmaceutical Corporation - NYMX PR Newswire NEW YORK, Aug. 10, 2016 NEW YORK, Aug. 10, 2016 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Nymox Pharmaceutical Corporation ("Nymox" or the "Company... More...>>
08/10/20163:59PMPRNUSSHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Nymox Pharmaceutical Corporation (NYMX)
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Nymox Pharmaceutical Corporation (NYMX) PR Newswire NEW YORK, Aug. 10, 2016 NEW YORK, Aug. 10, 2016 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers... More...>>
08/10/201612:36PMBWEQUITY ALERT: Rosen Law Firm Announces Investigation of Securities Claims Against Nymox Pharmaceutical Corporation
Rosen Law Firm, a global investor rights law firm, announces it is investigating potential securities claims on behalf of shareholders of Nymox Pharmaceutical Corporation (NASDAQ: NYMX) resulting from allegations that Nymox may have issued materially misleading business information to the investing public. On August 10... More...>>
06/22/20169:30AMGLOBENymox Reports Long-Term Prostate Cancer Results in 7 Year Prospective Study of 995 U.S. Middle-Aged and Elderly Men Without C...
HASBROUCK HEIGHTS, N.J., June 22, 2016 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ:NYMX) announced today results from the Company's 7 year prospective placebo controlled double blind studies of treatment of 995 U.S. men with the Company's lead drug fexapotide. Men who received fexapotide showed a major... More...>>
02/09/201610:00AMGLOBENymox Announces Prostate Cancer Clinical Trial Results From Completed 18 Month Endpoint Study
HASBROUCK HEIGHTS, N.J., Feb. 09, 2016 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ:NYMX) today announced results from the completion of the Company's U.S. 40 month (18 month outcomes) localized prostate cancer Phase 2 NX03-0040 clinical trial of fexapotide triflutate (NX-1207). The study successfully met... More...>>
02/04/201611:15AMGLOBENymox Announces Additional $2.1 Million Equity Financing
HASBROUCK HEIGHTS, N.J., Feb. 04, 2016 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ:NYMX) announced today private placement equity investment of US$2.1 Million. The investment was at $2.00 per share with no warrants. The investment was made by long-term Nymox shareholders. The Company has now... More...>>
12/31/20154:45PMGLOBENymox Files Current Financial Statements
HASBROUCK HEIGHTS, N.J., Dec. 31, 2015 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ:NYMX) is pleased to announce that today the Company has filed its third quarter 2015 and restated second quarter 2015 financial statements. The financial results are available at - http://www.sec.gov/cgi-bin/browse-edgar?company=nymox&owner=exclude&action=getcompany... More...>>
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:35 V:us D:20170627 19:06:31